Your browser doesn't support javascript.
loading
Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity.
Zubiaur, Pablo; Soria-Chacartegui, Paula; Boone, Erin C; Prasad, Bhagwat; Dinh, Jean; Wang, Wendy Y; Zugbi, Santiago; Rodríguez-Lopez, Andrea; González-Iglesias, Eva; Leeder, J Steven; Abad-Santos, Francisco; Gaedigk, Andrea.
Afiliación
  • Zubiaur P; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
  • Soria-Chacartegui P; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Boone EC; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
  • Prasad B; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Dinh J; Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
  • Wang WY; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Zugbi S; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Rodríguez-Lopez A; Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
  • González-Iglesias E; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
  • Leeder JS; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
  • Abad-Santos F; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Gaedigk A; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Clin Pharmacol Ther ; 114(5): 1033-1042, 2023 11.
Article en En | MEDLINE | ID: mdl-37528442
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistema Enzimático del Citocromo P-450 / Citocromo P-450 CYP2C19 Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2023 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistema Enzimático del Citocromo P-450 / Citocromo P-450 CYP2C19 Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2023 Tipo del documento: Article País de afiliación: España